Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
CAMBRIDGE, Mass., April 11, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day on Friday, May 4, 2018 starting at approximately 8:30 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at approximately 8:30 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
